Management of CKD Stage 4 Complications

Monitoring and Treatment

The American Diabetes Association recommends actively screening and treating anemia, secondary hyperparathyroidism, and metabolic acidosis every 3 months in CKD Stage 4 patients (eGFR 15-29 mL/min/1.73 m²), as these complications directly impact mortality and quality of life 1, 2, 3
The National Kidney Foundation suggests laboratory monitoring should occur every 3 months minimum and include serum electrolytes, hemoglobin and iron studies, calcium, phosphorus, and intact PTH, as well as albumin and weight assessment 1, 2, 4
The American College of Physicians recommends considering nephrology referral immediately when eGFR falls below 30 mL/min/1.73 m², as consultation at stage 4 CKD reduces costs, improves quality of care, and delays dialysis 1, 5, 6, 7

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends measuring hemoglobin at least annually in all CKD patients, but increase to every 3 months once stage 4 is reached, with anemia prevalence increasing dramatically at stage 4 (22-52% depending on diabetes status) 8
The European Renal Association suggests obtaining a complete blood count, absolute reticulocyte count, serum ferritin and transferrin saturation, and serum vitamin B12 and folate levels when anemia is detected (Hb <13 g/dL in men, <12 g/dL in women) 4
The American Society of Nephrology recommends prioritizing intravenous iron therapy before initiating ESAs when ferritin is <500 ng/mL and TSAT is <32%, with a typical dose of 200 mg weekly for 3 weeks, which raises hemoglobin by 1-2 g/dL within 2 months 4

The National Institute of Diabetes and Digestive and Kidney Diseases recommends measuring serum calcium and phosphorus every 3 months in all CKD Stage 4 patients, and measuring intact PTH at least once initially, then every 3 months if calcium or phosphorus levels are abnormal 3
The American College of Cardiology suggests ensuring vitamin D sufficiency by checking 25-hydroxyvitamin D levels and repleting as needed, and restricting dietary phosphorus and initiating phosphate binders if serum phosphorus is elevated 1, 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends monitoring serum bicarbonate every 3 months in all CKD Stage 4 patients, with a target of ≥22 mmol/L, which reduces bone disease complications and may slow CKD progression 3
The European Renal Association suggests administering oral sodium bicarbonate or sodium citrate to achieve target bicarbonate levels, starting with 650 mg sodium bicarbonate (approximately 8 mEq) three times daily and titrating based on serum bicarbonate response 3

The American Heart Association recommends not targeting hemoglobin >11 g/dL with ESA therapy, as this increases cardiovascular mortality without improving quality of life, and not stopping iron supplementation when hemoglobin normalizes, but continuing for 3 months to replenish stores and prevent cognitive symptom recurrence 9
The American College of Physicians suggests not combining ACE inhibitors with ARBs, as this increases hyperkalemia and acute kidney injury without cardiovascular or renal benefits, and not overlooking blood pressure monitoring during ESA therapy, checking with each dose, especially in patients with prior stroke or cardiovascular disease 4, 5, 7